Egyptian Drug Price Reform: New Trade Barrier Or Demand Driver?
This article was originally published in PharmAsia News
Executive Summary
Egypt, an emerging pharmaceutical market, is implementing a series of healthcare and drug pricing reforms. The new drug pricing regime, a streamlined registration process and the government's initiative to widen health insurance coverage, could help drive up domestic demand for pharmaceutical products, especially for branded generics in the country
You may also be interested in...
Dynamic Markets Need Dynamic Pricing: Roche Explores Differential Pricing Strategies In Emerging Markets
Roche experiments with a variety of tactics, including second brands, patient assistant programs, supporting private insurance and other ways to drive volume in highly fragmented markets.
Pharmas Assess Impact In Egypt; Local Player Hikma Less Exposed, Say Analysts
As drug makers restart their Egyptian operations, financial analysts have begun to assess the impact of recent events for the pharma industry. As the largest pharma market in the Middle East, Egypt has attracted both multinational and local drug makers, but local firms such as leading Jordanian pharma Hikma may see less disruption from political events than MNC counterparts, according to Credit Suisse analysts
Pharmas Assess Impact In Egypt; Local Player Hikma Less Exposed, Say Analysts
As drug makers restart their Egyptian operations, financial analysts have begun to assess the impact of recent events for the pharma industry. As the largest pharma market in the Middle East, Egypt has attracted both multinational and local drug makers, but local firms such as leading Jordanian pharma Hikma may see less disruption from political events than MNC counterparts, according to Credit Suisse analysts